Last Updated:
10 Mar 2026, 03:29:48 PM (IST)
FDC Limited
NSE: FDC BSE: FDC
NSE
378.05
6.15 (1.65%)
Prev Close
371.9
Open Price
375
Volume
52,686
Today Low / High
372 / 380
52 WK Low / High
349.25 / 527.8
Range
359 - 397
BSE
377.05
4.95 (1.33%)
Prev Close
372.1
Open Price
372.2
Volume
2,658
Today Low / High
372.05 / 379.65
52 WK Low / High
330.05 / 528.3
Range
358 - 396
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 378.05 (target range: 359 - 397), reflecting a change of 6.15 (1.65367%). On the BSE, it is listed at 377.05 (target range: 358 - 396), showing a change of 4.95 (1.33029%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
02 Mar
350.65
6.10%
27 Feb
364.90
-2.26%
26 Feb
366.60
-0.93%
25 Feb
370.20
-1.59%
24 Feb
372.20
-0.90%
23 Feb
370.30
1.04%
20 Feb
375.05
-1.64%
19 Feb
380.50
-1.04%
18 Feb
380.50
-0.35%
FDC Limited Graph
FDC Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for FDC Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 378.05, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 377.05 | 380.82 | 342.74 - 418.90 |
| 384.59 | 307.67 - 461.51 | ||
| 388.36 | 271.85 - 504.87 | ||
| Bearish Scenario | 377.05 | 373.28 | 335.95 - 410.61 |
| 369.51 | 295.61 - 443.41 | ||
| 365.74 | 256.02 - 475.46 |
Overview of FDC Limited
ISIN
INE258B01022
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
79,698
Market Cap
60,573,491,752
Last Dividend
5
Official Website
IPO Date
2002-07-01
DCF Diff
-523.47
DCF
893
Financial Ratios Every Investor Needs
Stock Dividend of FDC
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2026-02-11 | February 11, 26 | 5 | 5 | 2026-02-11 | 2026-03-07 | |
| 2024-11-22 | November 22, 24 | 5 | 5 | 2024-11-22 | 2024-12-06 | |
| 2020-03-19 | March 19, 20 | 0.8 | 0.8 | 2020-03-21 | 2020-03-31 | 2020-03-09 |
| 2017-08-08 | August 08, 17 | 2.25 | 2.25 | 2017-08-09 | 2017-09-18 | 2017-05-26 |
| 2016-03-17 | March 17, 16 | 2.25 | 2.25 | 2016-03-19 | 2016-03-23 | 2016-03-09 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,108.12 Cr | 1,272.38 Cr | 835.74 Cr | 0.3964 | 8.20 Cr | 482.65 Cr | 271.07 Cr | 266.79 Cr | 16.42 | 415.46 Cr | 0.1266 |
| 2024-03-31 | 1,935.20 Cr | 1,284.32 Cr | 650.88 Cr | 0.3363 | 18.48 Cr | 22.50 Cr | 303.37 Cr | 305.22 Cr | 18.59 | 440.17 Cr | 0.1577 |
| 2023-03-31 | 1,783.75 Cr | 655.79 Cr | 1,127.96 Cr | 0.6324 | 17.10 Cr | 17.20 Cr | 215.74 Cr | 194.04 Cr | 11.67 | 300.83 Cr | 0.1088 |
| 2022-03-31 | 1,525.75 Cr | 547.45 Cr | 978.29 Cr | 0.6412 | 15.85 Cr | 9.81 Cr | 220.51 Cr | 216.40 Cr | 12.82 | 329.78 Cr | 0.1418 |
| 2021-03-31 | 1,326.83 Cr | 426.96 Cr | 899.87 Cr | 0.6782 | 13.26 Cr | 9.31 Cr | 296.24 Cr | 301.35 Cr | 17.73 | 428.95 Cr | 0.2271 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 52.77 Cr | 2,713.80 Cr | 432.72 Cr | 2,281.0805 Cr | 21.17 Cr | -31.60 Cr | 375.03 Cr | 984.14 Cr | 0.00 Cr | 0.00 Cr | 547.36 Cr | 361.6373 Cr |
| 2024-03-31 | 25.42 Cr | 2,468.09 Cr | 370.92 Cr | 2,097.1690 Cr | 20.52 Cr | -4.90 Cr | 388.89 Cr | 949.47 Cr | 5.11 Cr | 12.33 Cr | 392.75 Cr | 310.6230 Cr |
| 2023-03-31 | 23.89 Cr | 2,342.94 Cr | 361.54 Cr | 1,982.0479 Cr | 28.32 Cr | 4.43 Cr | 328.54 Cr | 892.93 Cr | 5.86 Cr | 18.65 Cr | 348.49 Cr | 311.5576 Cr |
| 2022-03-31 | 37.73 Cr | 2,270.20 Cr | 313.84 Cr | 1,956.7904 Cr | 32.20 Cr | -5.52 Cr | 304.70 Cr | 838.64 Cr | 3.40 Cr | 0.98 Cr | 384.73 Cr | 272.1553 Cr |
| 2021-03-31 | 30.43 Cr | 1,956.23 Cr | 222.27 Cr | 1,734.1349 Cr | 14.66 Cr | -15.90 Cr | 214.92 Cr | 719.15 Cr | 110.30 Cr | 0.00 Cr | -261.12 Cr | 203.9991 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 364.1577 Cr | -246.8747 Cr | -91.3470 Cr | 267.4331 Cr | 27.0418 Cr | 52.7719 Cr | -96.7246 Cr | 266.7881 Cr | -0.0321 Cr | -81.1337 Cr | 17.0137 Cr |
| 2024-03-31 | 220.7674 Cr | -17.0832 Cr | -202.1572 Cr | 127.3742 Cr | 1.5337 Cr | 25.4201 Cr | -93.3932 Cr | 305.2233 Cr | -0.0759 Cr | -0.1468 Cr | -57.9576 Cr |
| 2023-03-31 | 154.9131 Cr | 11.1346 Cr | -179.9501 Cr | 41.8206 Cr | -13.8389 Cr | 23.8864 Cr | -113.0925 Cr | 257.8033 Cr | -9.6243 Cr | -0.1777 Cr | -23.8402 Cr |
| 2022-03-31 | 161.6522 Cr | -144.5669 Cr | -9.8366 Cr | 29.1080 Cr | 7.2938 Cr | 37.7253 Cr | -132.5442 Cr | 289.3901 Cr | -0.1357 Cr | 0.0000 Cr | -89.7751 Cr |
| 2021-03-31 | 207.0815 Cr | -77.1536 Cr | -129.3490 Cr | 144.5421 Cr | 0.5546 Cr | 30.4315 Cr | -62.5394 Cr | 389.8541 Cr | -2.9220 Cr | 0.0000 Cr | -4.9601 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 464.71 Cr | 286.42 Cr | 178.29 Cr | 0.3837 | 37.50 Cr | 28.30 Cr | 1.74 | 52.29 Cr | 0.0609 |
| 2025-09-30 | 473.03 Cr | 144.56 Cr | 328.47 Cr | 0.6944 | 18.62 Cr | 28.37 Cr | 1.75 | 54.44 Cr | 0.0600 |
| 2025-06-30 | 648.41 Cr | 209.23 Cr | 439.17 Cr | 0.6773 | 125.44 Cr | 121.35 Cr | 7.45 | 175.85 Cr | 0.1872 |
| 2025-03-31 | 491.89 Cr | 298.51 Cr | 193.38 Cr | 0.3931 | 38.42 Cr | 38.67 Cr | 2.38 | 70.06 Cr | 0.0786 |
| 2024-12-31 | 464.11 Cr | 160.92 Cr | 303.19 Cr | 0.6533 | 33.30 Cr | 37.04 Cr | 2.28 | 65.48 Cr | 0.0798 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 35.62 Cr | 416.71 Cr | 452.33 Cr | 166.53 Cr | 435.10 Cr | 1,133.61 Cr | 1,000.89 Cr | 2,885.55 Cr | 454.16 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 537.42 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,281.08 Cr |
| 2025-03-31 | 52.77 Cr | 484.65 Cr | 537.42 Cr | 110.29 Cr | 375.03 Cr | 1,088.72 Cr | 984.14 Cr | 2,713.80 Cr | 432.72 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 590.79 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,291.73 Cr |
| 2024-09-30 | 45.54 Cr | 545.24 Cr | 590.79 Cr | 174.80 Cr | 322.85 Cr | 1,147.02 Cr | 943.71 Cr | 2,688.08 Cr | 396.35 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 121.35 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 38.67 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 37.04 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 72.04 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 119.04 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2004-04-29 | April 29, 04 | 2:1 |
| 2002-05-14 | May 14, 02 | 10:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Joint MD & Executive Director
Nandan Mohan Chandavarkar
Gender: Not Specified
Year Born:
Senior Vice President Business Development
Mayank Tikkha
Gender: Not Specified
Year Born:
Chief Executive Officer of International Business & Executive Director
Ameya Ashok Chandavarkar
Gender: male
Year Born: 1978
Whole Time Director
Ashok Anand Chandavarkar
Gender: male
Year Born:
BR Head, MD & Director
Mohan Anand Chandavarkar
Gender: male
Year Born:
Vice President of Corporate Finance
Sanjay Jain
Gender: male
Year Born:
Vice President of Technical & Operations
Shashank Vyapari
Gender: male
Year Born:
Chief Financial Officer
Vishal Shah
Gender: male
Year Born:
Senior Vice President Human Resources
Zafrullah Khan
Gender: male
Year Born: 1968
Legal Head, Compliance Officer & Company Secretary
Varsharani Rajaram Katre
Gender: female
Year Born:
FAQs about FDC Limited
Who is the CEO of the company?
The CEO is Ameya Ashok Chandavarkar.
What is the current market price of the stock?
The current price is ₹372.05.
What is the 52-week price range?
The range is ₹349.25-527.8.
What is the market capitalization of the company?
The market capitalization is ₹6,057.35 crores.
What is the dividend yield?
The dividend yield is 1.34%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 27.95.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of FDC Limited (ISIN: INE258B01022) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹6,057.35 crores and an average daily volume of 79,698 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.